OverviewSuggest Edit

Neovasc Inc. is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™ for the treatment of refractory angina, the Tiara™ technology in development for the transcatheter treatment of mitral valve disease and a line of advanced biological tissue products that are used as key components in a variety of third-party medical products, such as vascular surgical patches and transcatheter heart valves.
TypePublic
Founded2008
HQRichmond, CA
Websiteneovasc.com
Employee Ratings3

Latest Updates

Share Price (Sept 2020)C$2.8
Cybersecurity ratingBMore

Key People/Management at Neovasc

Fred Colen

Fred Colen

President and Chief Executive Officer
Steve Rubin

Steve Rubin

Chairman
Bill Little

Bill Little

Chief Operating Officer
Brian McPherson

Brian McPherson

COO
Christopher Clark

Christopher Clark

Chief Financial Officer
Aaron J. Chalekian

Aaron J. Chalekian

Vice-President of Product Development & Manufacturing Engineering
Show more

Neovasc Office Locations

Neovasc has an office in Richmond
Richmond, CA (HQ)
5138 13562 Maycrest Way
Show all (1)

Neovasc Financials and Metrics

Neovasc Revenue

Market capitalization (15-Sept-2020)

63.0m

Closing stock price (15-Sept-2020)

2.8
Neovasc's current market capitalization is C$63 m.
Show all financial metrics

Neovasc Cybersecurity Score

Cybersecurity ratingPremium dataset

B

84/100

SecurityScorecard logo

Neovasc Online and Social Media Presence

Embed Graph

Neovasc News and Updates

Neovasc to Participate in H.C. Wainwright & Co. 22nd Annual Global Investment Conference

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - September 08, 2020 - Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory…

Neovasc Inc. Reports Results of Annual General Meeting of Shareholders

Vancouver, BC, Canada - (NewMediaWire) - September 3, 2020 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) is pleased to announce the results of the votes on matters considered at its Annual General Meeting of Shareholders held on September 3, 2020 in Vancouver, B.C. (the “Meeti…

Neovasc Announces US$12.6 Million Registered Direct Offering Priced At-the-Market

Vancouver - (NewMediaWire) - August 10, 2020 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 4,532,772 common shares at a…

Neovasc Reducer™ Featured In Germany’s Second Largest National Newspaper

VANCOUVER, Canada, MINNEAPOLIS, MN and FRANKFURT, Germany , July 24, 2020 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE --  Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that the Neovasc Reducer™ (the “Reducer”) was featured in a supplement titled: “Volkskrankheiten” or “Co…

Neovasc Announces Partial Prepayment of Convertible Debenture

VANCOUVER and MINNEAPOLIS - (NewMediaWire) - July 23, 2020 - Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN) announced today that Strul Medical Group LLC (“SMG”) exercised 1,424,049 of the 2,573,959 common share purchase warrants (the “May Warrants”) issued pursuant to a Securitie…

Neovasc Announces Circulatory System Devices Panel Meeting Date for Neovasc Reducer Device

VANCOUVER and MINNEAPOLIS, MN - (NewMediaWire) - July 09, 2020 -  Neovasc, Inc. ("Neovasc" or the "Company") (NASDAQ, TSX: NVCN), announced today that it has been informed by the U.S. Food and Drug Administration (FDA) that the Circulatory System Devices Panel of the Medical Devices Advisory Co…
Show more

Neovasc Blogs

Neovasc ReducerTM and TiaraTM Featured at Leading Industry Virtual Conferences

NASDAQ, TSX: NVCN   VANCOUVER and MINNEAPOLIS, June 29, 2020 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), today announced that the Neovasc Reducer™ (“Reducer”) and Tiara™ (“Tiara”) program were recently featured at two industry conferences. The Tiara Mitral Valve Replacement pro…

Neovasc Announces Closing of $11.5 MillionRegistered Direct Offering Priced At-The-Market

NASDAQ, TSX: NVCN   VANCOUVER and MINNEAPOLIS, June 16, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, …

NEOVASC ANNOUNCES $11.5 MILLION REGISTERED DIRECT OFFERINGPRICED AT-THE-MARKET

NASDAQ, TSX: NVCN Vancouver, Canada, June 12, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ: NVCN / TSX: NVCN) announced today that it has entered into definitive agreements with certain healthcare-focused institutional investors for the sale of an aggregate of 3,883,036 common shares at.…

Neovasc Reducer™ and Tiara™ Program to be Highlighted at Leading Industry Virtual Conferences

NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 9, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, ann…

Neovasc Announces Closing of Final Convertible Debt Issuance for Gross Proceeds of US $5.0 Million

NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 4, 2020 – Neovasc Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally invasive devices for the treatment of refractory angina, ann…

Neovasc Reducer™ Spotlighted in Leading German Public Television Program

Elective Interventional Procedures Resume in Germany   NASDAQ, TSX: NVCN VANCOUVER and MINNEAPOLIS, June 3, 2020 – Neovasc, Inc. (“Neovasc” or the “Company”) (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, and minimally inva…
Show more

Neovasc Frequently Asked Questions

  • When was Neovasc founded?

    Neovasc was founded in 2008.

  • Who are Neovasc key executives?

    Neovasc's key executives are Fred Colen, Steve Rubin and Bill Little.

  • Who are Neovasc competitors?

    Competitors of Neovasc include Apollo Endosurgery, Liberator Medical Supply and Medequip.

  • Where is Neovasc headquarters?

    Neovasc headquarters is located at 5138 13562 Maycrest Way, Richmond.

  • Where are Neovasc offices?

    Neovasc has an office in Richmond.

  • How many offices does Neovasc have?

    Neovasc has 1 office.